Aimmune Therapeutics Inc (NASDAQ:AIMT) saw some unusual options trading on Tuesday. Stock investors bought 2,062 put options on the stock. This is an increase of 1,474% compared to the average volume of 131 put options.
Shares of NASDAQ:AIMT traded down $0.43 during trading on Wednesday, reaching $21.13. The stock had a trading volume of 3,481 shares, compared to its average volume of 572,946. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average of $19.51. The company has a market cap of $1.35 billion, a PE ratio of -5.79 and a beta of -0.07. Aimmune Therapeutics has a 1-year low of $16.95 and a 1-year high of $36.12.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.08). During the same period in the previous year, the business earned ($0.91) earnings per share. Research analysts expect that Aimmune Therapeutics will post -3.82 earnings per share for the current year.
Several analysts have commented on the company. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 30th. Wedbush set a $79.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 11th. Royal Bank of Canada dropped their price objective on Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Credit Suisse Group assumed coverage on Aimmune Therapeutics in a report on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, ValuEngine raised Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $42.50.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: What are no-load funds?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.